SCHEMBL12430880

SCHEMBL12430880

CN1CCN(c2cc(Nc3cc(C4CC4)[nH]n3)nc(Oc3ccc4ccccc4c3)n2)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 9/20 0.59
AURKA O14965 2/20 0.58
NTRK1 P04629 2/20 0.58
TBK1 Q9UHD2 2/20 0.55
PIK3C3 Q8NEB9 1/20 0.55
IGF1R P08069 7/20 0.53
SRC P12931 3/20 0.52
RET P07949 2/20 0.51
BMPR1B O00238 1/20 0.51
PLK4 O00444 1/20 0.51
EPHB6 O15197 1/20 0.51
STK10 O94804 1/20 0.51
PRKD3 O94806 1/20 0.51
PAK4 O96013 1/20 0.51
ABL1 P00519 1/20 0.51
INSR P06213 1/20 0.51
LCK P06239 1/20 0.51
FYN P06241 1/20 0.51
YES1 P07947 1/20 0.51
LYN P07948 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12430874 0.89 PIK3C3 (0.54) EGFRAURKANTRK1PIK3C3IGF1R
SCHEMBL16065644 0.87 EGFR (0.59) EGFRAURKANTRK1TBK1PIK3C3
SCHEMBL15705070 0.84 EGFR (0.58) EGFRAURKANTRK1TBK1PIK3C3
SCHEMBL13054752 0.84 EGFR (0.53) EGFRAURKANTRK1TBK1PIK3C3
SCHEMBL12430873 0.83 IGF1R (0.55) PIK3C3IGF1R
SCHEMBL12430800 0.82 AURKA (0.79) EGFRAURKANTRK1TBK1IGF1R
SCHEMBL16065533 0.81 EGFR (0.53) EGFRAURKANTRK1TBK1PIK3C3
SCHEMBL12430864 0.79 IGF1R (0.53) PIK3C3IGF1R
SCHEMBL10122967 0.78 AURKA (0.76) AURKANTRK1TBK1IGF1RSRC
SCHEMBL12430868 0.78 NEK1 (0.58) PIK3C3IGF1RPAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, AURKC, AURKA EGFR 480/4885AURKA 3/4885NTRK1 2111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.